DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical ...

Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an ...

Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID-19 and Ebola -- while also minimizing side effects and reducing the odds of ...

Elon Musk validated the use of GLP-1 drugs in a post on X on Wednesday. But Robert F. Kennedy Jr. has said he's opposed to Americans using them to fight obesity.

Acrivon Therapeutics develops innovative cancer therapies with companion diagnostics. Read why ACRV stock has upside ...

A grant from the National Institute of Health to the University of Arkansas for Medical Sciences will help researchers explore promising pituitary gland treatments.

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

The Institute of Cancer Research, London, is the second-ranked academic research centre in the UK - according to the Times Higher Education league table of university research quality and impact ...

Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024.

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.